Prognosis of chronic pulmonary aspergillosis in patients with pulmonary non-tuberculous mycobacterial disease

Naito, Maiko; Kurahara, Yu; Yoshida, Shiomi; Ikegami, Naoya; Kobayashi, Takehiko; Minomo, Shojiro; Tachibana, Kazunobu; Tsuyuguchi, Kazunari; Hayashi, Seiji; Suzuki, Katsuhiro

doi:10.1016/j.resinv.2018.04.002

Cited by 26 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NTM is a cause of smear-positive/ M . tuberculosis GeneXpert-negative mycobacterial infection with a very high risk of concurrent or precedent CPA development [ 32 ]. CPA patients with NTM have a particularly poorer prognosis [ 32 ].…”

Section: How Is Cpa Differentiated From Ptb and Ptbld?mentioning

confidence: 99%

Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern

Bongomin

2020

PLoS Pathog

View full text Add to dashboard Cite

How common is CPA after treated PTB? CPA is a progressive respiratory syndrome that largely occur in immunocompetent or subtly immunocompromised individuals with underlying structural lung diseases, most commonly treated TB [11]. Residual cavities remain in between 20% to 40% of lungs of patients following treatment for PTB [12,13]. Cavitation and ectatic lesions in PTBLD allows saprophytic colonisation and growth of Aspergillus species following inhalation of infectious spores from the environment. This leads to expansion of the existing or creation of new cavities with associated parenchymal and pleural damage [11]. A complex mixture of Aspergillus hyphae, tissue debris, inflammatory cells, and mucin known as a fungal ball (aspergilloma) may form in these cavities [11]. The significance of treated PTB in the pathogenesis of CPA was established by a large cohort study across over 50 clinics in Great Britain in the mid-to late 1960s [14]. In this landmark study, 544 patients who had a persistent cavity of at least 2.5 cm in diameter and negative M. tuberculosis bacilli in their sputum for at least a year were studied. About 25% of the patients had positive Aspergillus precipitins (i.e., precipitating immunoglobulin M [IgM] and immunoglobulin G

show abstract

Section: How Is Cpa Differentiated From Ptb and Ptbld?mentioning

confidence: 99%

Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern

Bongomin

2020

PLoS Pathog

View full text Add to dashboard Cite

show abstract

“…Six-monthly respiratory clinic follow-up in the 2 years after TB treatment may be useful in the monitoring and management of possible COPD and bronchiectasis in a subset of patients with chronic lung disease, who might need pulmonary rehabilitation. Clinicians should also be aware of the possibility, and associated higher mortality, of NTM-Aspergillus coinfection (Jhun et al, 2017;Naito et al, 2018).…”

Section: Introduction and Approachmentioning

confidence: 99%

Post tuberculosis treatment infectious complications

Hsu

Irfan

Jabeen

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Following greater attention and follow-up of patients with treated pulmonary tuberculosis (TB), it has emerged that infections are more likely to occur in this cohort of patients. This comes as no surprise, as pulmonary TB is a destructive process that leads to cicatrization, alteration of parenchyma, bronchiectasis, and scarring of the lung, with reduction of lung volumes and an impact on pulmonary function. In addition to relapse and re-infection with TB, other pathogens are increasingly recognized in post-TB patients. This paper serves as a summary and guide on how to approach the post-TB patient with new signs and symptoms of pulmonary infection in order to ensure optimal management and rehabilitation.

show abstract

“…Cystic fibrosis (CF) is an autosomal recessive disease, caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene predominantly found in Caucasian populations, is characterized by CFTR dysfunction [61]. The CF patients have decreased secretion of chloride and bicarbonate across the CFTR channel and increased absorption of sodium through the epithelial sodium channel, • Bronchiectasis [53][54][55][56] • Post TB infection [57][58][59][60] • Cystic fibrosis [61][62][63][64][65][66] • ABPA [67][68][69][70][71][72][73] • Impaired mucociliary clearance [74][75][76][77] b) Genetic defects • Genetic defects in genes related with immune response, CFTR, cilia, and connective tissue [74,[78][79][80][81][82][83]…”

Section: (B) Cystic Fibrosismentioning

confidence: 99%

“…Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to the presence of Aspergillus fumigatus associated with asthma and CF [67][68][69]. Patients with ABPA are at risk of developing PNTM [70,71] and the infection with MAC and M. kansasii is associated with a higher risk of developing chronic pulmonary aspergillosis (CPA) [72], with poor prognosis related to the use of systemic corticosteroid treatment [72]. The probability to develop bronchiectasis decreases if patients with ABPA receive proper treatment [73] (Table 2).…”

Section: (C) Allergic Bronchopulmonary Aspergillosismentioning

confidence: 99%

Pulmonary non-tuberculous mycobacterial infections: current state and future management

Chin

Sarmiento

Alvarez-Cabrera

et al. 2019

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Currently, there is a trend of increasing incidence in pulmonary non-tuberculous mycobacterial infections (PNTM) together with a decrease in tuberculosis (TB) incidence, particularly in developed countries. The prevalence of PNTM in underdeveloped and developing countries remains unclear as there is still a lack of detection methods that could clearly diagnose PNTM applicable in these low-resource settings. Since non-tuberculous mycobacteria (NTM) are environmental pathogens, the vicinity favouring host-pathogen interactions is known as important predisposing factor for PNTM. The ongoing changes in world population, as well as socio-political and economic factors, are linked to the rise in the incidence of PNTM. Development is an important factor for the improvement of population well-being, but it has also been linked, in general, to detrimental environmental consequences, including the rise of emergent (usually neglected) infectious diseases, such as PNTM. The rise of neglected PNTM infections requires the expansion of the current efforts on the development of diagnostics, therapies and vaccines for mycobacterial diseases, which at present, are mainly focused on TB. This review discuss the current situation of PNTM and its predisposing factors, as well as the efforts and challenges for their control.

show abstract

Prognosis of chronic pulmonary aspergillosis in patients with pulmonary non-tuberculous mycobacterial disease

Cited by 26 publications

References 16 publications

Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern

Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern

Post tuberculosis treatment infectious complications

Pulmonary non-tuberculous mycobacterial infections: current state and future management

Contact Info

Product

Resources

About